|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03692 HANSOH PHARMA
Nominal 
35.960 -2.860 (-7.367%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 7,433,559 | 14.266% | 12,260,814 | 10,103,806 | 9,382,410 | 9,935,141 |
| Cost of Sales | (660,786) | 14.082% | (1,105,408) | (1,030,863) | (867,010) | (870,042) |
| Gross Profit | 6,772,773 | 14.284% | 11,155,406 | 9,072,943 | 8,515,400 | 9,065,099 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 3,688,152 | 18.279% | 5,085,182 | 3,766,155 | 2,948,428 | 3,300,082 | |
| Taxation | (553,223) | 40.891% | (713,357) | (488,652) | (364,681) | (587,180) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,134,929 | 15.021% | 4,371,825 | 3,277,503 | 2,583,747 | 2,712,902 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (510,760) | 38.392% | (988,570) | (838,326) | (250,943) | (111,275) |
| Depreciation & Amortisation | 197,274 | -8.993% | 401,349 | 366,381 | 344,602 | 278,467 |
| Directors' Emoluments | -- | -- | 39,526 | 41,912 | 33,123 | 39,608 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 53.000 | 15.217% | 74.000 | 55.000 | 44.000 | 46.000 |
| DPS (cts) | 21.133 | -- | 31.056 | 19.311 | 8.711 | 7.320 |
| Dividend Payout Ratio (%) | 39.873% | -- | 41.968% | 35.110% | 19.797% | 15.913% |
| Cash flow per share ($) | -- | -- | 0.651 | 0.526 | 0.463 | 0.435 |
| NBV per share ($) | 5.229 | -- | 4.832 | 4.347 | 3.824 | 3.382 |
| Remarks: | Real time quote last updated: 20/08/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,134,929 |
| %Change | 15.021% |
| EPS / (LPS) | RMB 0.530 |
| NBV Per Share (¥) | RMB 5.229 |